Octapharma AB - July 14, 2016

$117.00
The investigation of out-of-inspection (OOS) results in the stability studies under licensed conditions is deficient in that it failed to identify both the route cause(s) that led to the OOS results and effective and preventative actions (CAPA) to remedy the problem.